КОМПЛЕМЕНТ ПРИ ПАТОЛОГИЯХ, ВОЗМОЖНОСТЬ КОРРЕКЦИИ С ПОМОЩЬЮ НОВОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА, БЛОКИРУЮЩЕГО АЛЬТЕРНАТИВНЫЙ ПУТЬ

Two monoclonal antibodies were developed and were shown to block the complement system alternative pathway (AP) activation at the stage of assembly and activation of C3 convertase. The humanized antibody hC34 specific to a binding site on α’2 determinant of С3с fragment inhibited in vitro the human complement activation by 90% at a dose of 3 μg/ml of blood serum. The antibody 3А8 specific to rat complement C3 component and similar to antibody hC34 was demonstrated to be pharmacologically active in model of closed craniocerebral injury (data of functional and histological studies). The results of this study indicate the humanized antibody hc34 to be promising for treatment of central nervous system pathologies and of other diseases associated with complement hyperactivation.